Witt, Karsten http://orcid.org/0000-0002-9384-3474
Levin, Johannes
van Eimeren, Thilo
Hasan, Alkomiet
Ebersbach, Georg
Bähr, Mathias
Becktepe, Jos
Berg, Daniela
Brockmann, Kathrin
Buhmann, Carsten
Ceballos-Baumann, Andrés
Claßen, Joseph
Deuschl, Cornelius
Deuschl, Günther
Dodel, Richard
Ebersbach, Georg
Eggers, Carsten
van Eimeren, Thilo
Fanciulli, Alessandra
Fimm, Bruno
Folkerts, Ann-Kristin
Gausepohl, Madeleine
Hasan, Alkomiet
Hermann, Wiebke
Hilker-Roggendorf, Rüdiger
Höglinger, Günter
Höllerhage, Matthias
Hopfner, Franziska
Jost, Wolfgang
Kalbe, Elke
Kassubek, Jan
Klebe, Stephan
Klein, Christine
Klietz, Martin
Köglsperger, Thomas
Kühn, Andrea
Krack, Paul
Krismer, Florian
Kuhlenbäumer, Gregor
Levin, Johannes
Liepelt-Scarfone, Inga
Lingor, Paul
Loewenbrück, Kai
Löhle, Matthias
Lorenzl, Stefan
Maaß, Sylvia
Maetzler, Walter
Menzel, Regina
Meyer, Philipp T.
Mollenhauer, Brit
Neumann, Manuela
Odin, Per
Outeiro, Tiago
Pötter-Nerger, Monika
Reese, René
Reetz, Kathrin
Rieß, Olaf
Ruf, Viktoria
Schneider, Anja
Schrader, Christoph
Schnitzler, Alfons
Seppi, Klaus
Sixel-Döring, Friederike
Storch, Alexander
Tönges, Lars
Trenkwalder, Claudia
van Eimeren, Thilo
Walter, Uwe
Wächter, Tobias
Warnecke, Tobias
Wegner, Florian
Winkler, Christian
Witt, Karsten
Woitalla, Dirk
Zeuner, Kirsten
Bantel, Martina
Witt, Jonas L.
,
Funding for this research was provided by:
Carl von Ossietzky Universität Oldenburg
Article History
Received: 23 May 2024
Revised: 5 July 2024
Accepted: 7 July 2024
First Online: 24 July 2024
Declarations
:
: K.W. has received funding from the Deutsche Forschungsgemeinschaft (German Research Association) and STADAPHARM GmbH outside the present study. He has received honoraria for presentations/advisory boards/consultations from BIAL, Indorsia, Boston Scientific and STADAPHARM GmbH, outside the present study. He has received royalties from Thieme Press and Elsevier Press. He serves as an editorial board member of Wileys “Parkinson’s Disease”, “Behavioural Neurology” and PLOSone. J.L. reports speaker fees from Bayer Vital, Biogen, EISAI, TEVA, Zambon, Esteve, Merck and Roche; consulting fees from Axon Neuroscience, EISAI and Biogen; author fees from Thieme medical publishers and W. Kohlhammer GmbH medical publishers and is inventor in a patent “Oral Phenylbutyrate for Treatment of Human 4-Repeat Tauopathies” (PCT/EP2024/053388) filed by LMU Munich. In addition, he reports compensation for serving as chief medical officer for MODAG GmbH, is beneficiary of the phantom share programme of MODAG GmbH and is inventor in a patent “Pharmaceutical Composition and Methods of Use” (EP 22 159 408.8) filed by MODAG GmbH, all activities outside the submitted work. T.v.E. received funding from the German Research Foundation (DFG) and the Brandau-Laibach Stiftung. He received honoraria for consulting and advisory work from Lundbeck Foundation and Lundbeck Pharma, Orion Pharma, GT Gain Therapeutics SA and ICON. He received materials from Life Molecular Imaging and Lilly. He owns stocks in NVIDIA, Microsoft and I.B.M. A.H. was a member of advisory boards of Boehringer Ingelheim, Lundbeck, Janssen, Otsuka, Rovi and Recordati and received paid speakership by these companies as well as by AbbVie and Advanz. He is editor of the German schizophrenia guideline. G.E. has received honoraria for presentations (advisory boards/consultations) from AbbVie Pharma, BIAL Pharma, Boehringer GmbH, Britannia Pharma, Desitin Pharma, ESTEVE Pharma, Neuraxpharm GmbH, STADAPHARMA GmbH and Zambon Pharma. He has received royalties from Kohlhammer Press and Thieme Press.